NCT05058755View on ClinicalTrials.gov

Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma

NACompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2023

Conditions
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Interventions
DRUG

tislelizumab, azacytidine, lenalidomide

"tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days."

DRUG

tislelizumab, etoposide, pegaspargase

"tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days"

Trial Locations (1)

200092

Xinhua Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT05058755 - Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma | Biotech Hunter | Biotech Hunter